Total : 1 View more »
Pathumwan, Bangkok Thailand
Child and Babycare Products, Healthcare Preparations or Products, Healthcare or Screening Services, Baby Foods, Health Supplements...
TEL: 662-2679048-51
FAX: 662-2679043
Total : 23 View more »
Analysts are looking for EPS of 90c on revenue of $7.76B. The consensus range is 88c-91c for EPS, and $7.45B-$8.15B for revenue, according to First Call.
http://seekingalpha.com/article/166281-earnings-preview-abbott-labs?source=yahoo
SAN FRANCISCO (MarketWatch) -- Abbott Laboratories said late Wednesday that it agreed to buy optical device maker Visiogen Inc. for $400 million in cash. The acquisition of privately-held Visiogen will expand Abbott's vision care portfolio into next-generation intraocular lenses, or devices used to
WASHINGTON (AP) -- Drug and medical-device company Abbott Laboratories is scheduled to report earnings for the third quarter on Wednesday. The following is a summary of
http://finance.yahoo.com/news/Earnings-Preview-Abbott-apf-988328403.html?x=0&.v=3
Its best-selling drug, the TriCor cholesterol treatment, sold in partnership with Abbott, faces a threat from generic competition as of 2011. Operating margins of about 18 per cent are also below the 25 per cent typical of a speciality pharma company.
Total : 37 View more »
Oct 30, 2009 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend, our proprietary pattern recognition system, called an Uptrend for Abbott Laboratories (NYSE:ABT) on May 12, 2009 at $45.38.
Since then, Abbott Laboratories has returned 12.6% as of today's recent price of $51.10. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nyse profit securities trial
Companies: Abbott Laboratories (ABT)
Nov 02, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
Abbott Laboratories has acquired Evalve, Inc., a designer, developer, and manufacturer of devices that enable the repair of cardiac valves. Abbott Laboratories is a diversified pharmaceuticals healthcare company. Both the companies are based in US.
Abbott acquired the remaining outstanding equity of Evalve that it did not already own for an upfront payment of $320 million, plus a $90 million payment if certain regulatory milestones are met.
Announcement (September 10, 2009):
Abbott Laboratories has entered into a definitive agreement to acquire the remaining 90% outstanding equity of Evalve, Inc. The transaction is valued at approximately $410 million.
Cooley Godward Kronish LLP is acting as advisor to Evalve.
Deal Value (US$ Million) 410 Deal Type Acquisition Sub-Category Majority Acquisition Deal Status Completed: 2009-11-02
Deal Participants
Target (Company) Evalve, Inc. Acquirer (Company) Abbott Laboratories
Deal Rationale
The acquisition enables Abbott to enhance its business in non-surgical treatment for structural heart diseases and to broaden its medical devices portfolio.
% Acquisition 90%
Tags: acquisition advisor business equity healthcare manufacturer medical pharmaceuticals structural
Companies: Abbott Laboratories (ABT)
Oct 23, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
A consortium of investors has sold Visiogen, Inc., an ophthalmic medical device company, to Abbott Laboratories, a diversified pharmaceuticals healthcare company. Both Abbott Laboratories and Visiogen are based in the US.
The consortium includes Technology Partners, Novartis Venture Fund, Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures, and Foundation Medical Partners.
Announcement (September 2, 2009):
A consortium of investors has agreed to sell Visiogen to Abbott Laboratories for $400 million in cash.
The transaction is expected to close in the fourth quarter of 2009.
J.P. Morgan Securities, Inc. is acting as financial advisor to Visiogen and Jones Day is acting as legal advisor to Abbott Laboratories.
Deal Value (US$ Million) 400 Deal Type Venture Finance Sub-Category Exit Deal Status Completed: 2009-10-20
Deal Participants
Target (Company) Visiogen, Inc. Acquirer (Company) Abbott Laboratories
Deal Rationale
By combining Visiogen's accommodating lens technology with Abbott's existing medical optics portfolio expands Abbott's ability to offer a set of refractive options to its ophthalmic customers and the patients. It would also allow Abbott Medical Optics to enter the accommodating intraocular lens (IOL) segment and enhance its IOL portfolio that includes the Tecnis(R) Multifocal lens.
Tags: advisor foundation healthcare legal medical optics pharmaceuticals securities technology
Oct 22, 2009 (Fresh Brewed Media via COMTEX) --
Abbott Laboratories (ABT) appears to be on the move today and is now at $51.34, up $0.18 (0.35%) on volume of 650,836 shares traded. Over the last 52 weeks the stock has ranged from a low of $41.27 to a high of $57.40. ABT was covered in a Lee Allen report today. To read the report, and get Lee's thoughts on this earnings season, go to www.marketintelligencecenter.com/la102209 . Abbott Laboratories stock has been showing support around $50.49 and resistance in the $52.29 range. Technical indicators for the stock are bullish and S&P gives ABT a positive 4 STARS (out of 5) buy ranking. If you are looking for a hedged play on ABT the stock seems like it could be a candidate for a January out-of-the-money bull-put credit spread below the 46 range.
ABR-Seven Summits Strategic Investments NewsBite Goto www.iotogo.com/18w1 for our free report titled, The 18 Ways To Know When It's Time To Dump A Stock
Companies: Abbott Laboratories (ABT)
Total : 323 View more »
News and project information on the Abbott Laboratories Biotech Facility, Barceloneta
http://www.pharmaceutical-technology.com/projects/puertorico/
Welcome To The Family: Abbott Medical Optics Joins Our Team The initials are the same, but the 3,600 employees of AMO, formerly Advanced Medical Optics, are now part of Abbott as the transaction to acquire this established global leader in vision care has been completed.
The CLAVE Connector is an exclusive proprietary product manufactured by ICU Medical which is available through Abbott Laboratories and independent international specialty distributors.
Gent (Belgium) – July 12, 2002 - Innogenetics announced today a new distribution arrangement, whereby the Innogenetics’ LiPA HLA tissue typing products will be marketed worldwide by both Innogenetics and Abbott Laboratories.
http://www.innogenetics.com/site/pressview.asp?id=101&lang=E
powered by 
Total : 7,980,000 View more »
Discovers, develops, manufactures and sells pharmaceutical and nutritional products such as drug delivery systems, antibiotics and prepared infant formulas. Includes investor an ...
Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals health care company. It has 72,000 employees and operates in over 130 countries. [1]
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates.
http://www.abbott.com/global/url/content/en_US/50:50/general_content/General_Content_00013.htm
Get detailed information on ABBOTT LABORATORIES (ABT) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest company ...
Navigation [accesskey 1] Content [accesskey 2] Site Search [accesskey 3] Job Seekers Login [accesskey 4] top of page [accesskey 5] PharmiWeb.com, From PharmiWeb Solutions PharmiWeb.com from PharmiWeb Solutions PharmiWeb.com Home Page 19 June 2008 Select a company 1st Pharma People 20:20 Selection
http://www.pharmiweb.com/events/event.asp?eventId=4133&channel=2
Oncology RD is currently booming with pharmaceuticals on a quest to develop effective cancer drugs. The established standard of care – surgery, radiotherapy and chemotherapy is fast giving way to a high-tech array of targeted therapies.
http://www.pharmiweb.com/events/event.asp?eventId=4023§ion=howto